Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance...
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
About this item
Full title
Author / Creator
Liu, Bowen , Wang, Tianjiao , Wang, Huawei , Zhang, Lu , Xu, Feifei , Fang, Runping , Li, Leilei , Cai, Xiaoli , Wu, Yue , Zhang, Weiying and Ye, Lihong
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant breast cancer remains largely unexplored. Here, we were interested in the...
Alternative Titles
Full title
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c92a82af67b449619641593a9fcda312
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c92a82af67b449619641593a9fcda312
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-018-0577-5
